Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.
|
31244936 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This underscores the need for combinatorial approaches with focus on PXR antagonism to improve drug effectiveness in hepatocellular carcinoma.<b>Abbreviations:</b> HCC: Hepatocellular Carcinoma; FDA: Food and Drug Administration; TGF-β: Transforming growth factor-β; PXR: Pregnane X receptor; CAR: Constitutive androstane receptor; P-gp/ABCB1: P-glycoproteins/ATP-binding cassette transporter subfamily B member 1; MRP1/ABCC1 and MRP2/ABCC2: Multidrug-resistance associated proteins; BCRP/ABCG2: Breast cancer resistant protein; DMEs: Drug-metabolizing enzymes; CFDA: 5,6-carboxyfluorescein diacetate; ETS1: Transcription factor E26 transformation specific sequence 1.
|
31739702 |
2019 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy.
|
30779721 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results indicate that elevated ABCB1 expression induced by C-terminal truncation of HBx was responsible for doxorubicin resistance in HCC.
|
30982500 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we tested the P-gp interaction of some A<sub>3</sub> adenosine receptor agonists that are being developed for the treatment of chronic diseases, including rheumatoid arthritis, psoriasis, chronic pain, and hepatocellular carcinoma.
|
31127007 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Repression of RNA pol III-dependent transcription by chemical inhibition or knockdown of BRF1 RNA pol III transcription initiation factor subunit (BRF1) enhanced HCC cell sensitivity to doxorubicin, suggesting that MAF1 regulates doxorubicin resistance in HCC by controlling RNA pol III-dependent transcription.
|
31645432 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We used qRT-PCR to measure expressions of miR-122, β-catenin and MDR1 in four HCC cell lines.
|
30539797 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
|
30801960 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings establish a novel miRNA-based approach for autophagy interference to reverse doxorubicin resistance in future chemotherapy regimens against human HCC.
|
31695022 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition.
|
31354912 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consequently, P-gp will play an important role in the disposition of cinobufotalin <i>in vivo</i>, which provided a new combination therapy for the clinical treatment of HCC.
|
31156437 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data indicate that the miR-338-5p/EGFR/ABCB1 regulatory loop plays a critical role in HCC, and a negative correlation between miR-338-5p and EGFR or ABCB1 was also detected in HCC clinical samples.
|
29527329 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review outlines the roles and principal mechanisms of p53 and P-gp mediated chemoresistance in HCC.
|
29772519 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We tested whether the uremic toxin indoxyl sulfate (IS), an endogenous ligand of the transcription factor aryl hydrocarbon receptor, could change the expression of the following liver transporters involved in drug clearance: <i>SLC10A1</i>, <i>SLC22A1</i>, <i>SLC22A7</i>, <i>SLC47A1</i>, <i>SLCO1B1</i>, <i>SLCO1B3</i>, <i>SLCO2B1</i>, <i>ABCB1</i>, <i>ABCB11</i>, <i>ABCC2</i>, <i>ABCC3</i>, <i>ABCC4</i>, <i>ABCC6</i>, and <i>ABCG2</i> We showed that IS increases the expression and activity of the efflux transporter P-glycoprotein (P-gp) encoded by <i>ABCB1</i> in human hepatoma cells (HepG2) without modifying the expression of the other transporters.
|
29222397 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition.
|
29568938 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway.
|
29968951 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
All of these results indicate that Baicalein can reverse P-gp-mediated MDR in HCC and may thus be useful for the treatment of drug-resistant HCC.
|
29571250 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
P-glycoprotein or membrane pump induced drug efflux and altered prosurvival Bcl-2 expression are key mechanisms for drug resistance leading to failure of chemotherapy in HCC.
|
29208281 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using in vitro assays, we show that repeated miRNA treatments resulted in gradual reduction of HCC cell proliferation and reversal of doxorubicin resistance.
|
29758233 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Multidrug resistance (MDR) due to overexpression of MDR1 is a major obstacle that hinders the treatment of hepatocellular carcinoma (HCC).
|
29563873 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previous researches indicated that cyclooxygenase-2 (Cox-2) might be involved in P-glycoprotein (P-gp)-mediated multidrug resistance in hepatocellular carcinoma cells.
|
28342979 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway.
|
28968929 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CDKN2B is critical for verapamil-mediated reversal of doxorubicin resistance in hepatocellular carcinoma.
|
29299129 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
|
28464252 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multidrug resistance (MDR) due to overexpression of P-glycoprotein (P-gp) is a major obstacle that hinders the treatment of hepatocellular carcinoma (HCC).
|
28769563 |
2017 |